Sugi Predict

Sugi Predict / Compounds / SCHEMBL1817697

SCHEMBL1817697

SCHEMBL1817697

O=C(O)C1(Cc2ccccc2Cl)CCCN1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ SLC6A2 P23975 6/20 0.42
▸ SLC6A4 P31645 6/20 0.42
▸ SLC6A3 Q01959 6/20 0.42
▸ CYP2D6 P10635 5/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ARG1 P05089 1/20 0.40
▸ ARG2 P78540 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.39
▸ CTBP2 P56545 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23273785 1.00 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPK1SLC6A2
SCHEMBL29274952 0.84 ARG1 (0.41) ALDH1A1MEN1KMT2ASLC6A2SLC6A4
SCHEMBL1817740 0.84 ARG1 (0.41) ALDH1A1MEN1KMT2ASLC6A2SLC6A4
SCHEMBL1820778 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL27765087 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL29349629 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL1821118 0.83 SLC6A2 (0.40) ALDH1A1SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL1815120 0.83 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL23273782 0.83 SLC6A2 (0.40) ALDH1A1SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL28131276 0.83 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154568-A1 NON-CANONICAL INSULINS AND THEIR USES California Institute of Technology (US) 2017-04-19 — — EP claimed
WO-2015191705-A1 NON-CANONICAL INSULINS AND THEIR USES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-12-17 — — WO claimed
US-20150353619-A1 Non-Canonical Insulins and Their Uses CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-12-10 — — US claimed
US-12214018-B2 Glucose responsive insulins PROTOMER TECHNOLOGIES, INC. (US) 2025-02-04 — — US disclosed
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-07-02 — — US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 — — CN disclosed
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-03-12 — — US disclosed
EP-4299134-A2 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO Bach Biosciences, LLC (US) 2024-01-03 — — EP disclosed
CN-116917297-A Aromatic boron-containing compounds and insulin analogues 原聚体科技公司 2023-10-20 — — CN disclosed
EP-3154594-B1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO BACH BIOSCIENCES LLC (US) 2023-07-19 — — EP disclosed
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS PROTOMER TECHNOLOGIES, INC. 2023-05-04 — — US disclosed
WO-2008128064-A2 TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS TRUSTEES OF TUFTS COLLEGE (US) 2008-10-23 — — WO disclosed
WO-2008119005-A1 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 — — WO disclosed
WO-2008118848-A1 N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 — — WO disclosed
WO-2008116053-A2 FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 — — WO disclosed
WO-2008116054-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 — — WO disclosed
EP-1948243-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF Aeris Therapeutics, Inc. (US) 2008-07-30 — — EP disclosed
WO-2008022015-A2 RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-02-21 — — WO disclosed
WO-2007055950-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF AERIS THERAPEUTICS, INC. (US) 2007-05-18 — — WO disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12214018-B2 Glucose responsive insulins GLP1R, GPR119, IAPP ALDH1A1 4504/4885MEN1 499/4885KMT2A 2469/4885
US-20150353619-A1 Non-Canonical Insulins and Their Uses IAPP, IDE, INSR ALDH1A1 4779/4885MEN1 430/4885KMT2A 4095/4885
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 ALDH1A1 749/4885MEN1 4181/4885KMT2A 3355/4885
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS GPR119, GLP1R, IAPP ALDH1A1 1361/4885MEN1 609/4885KMT2A 2528/4885
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 ALDH1A1 323/4885MEN1 4377/4885KMT2A 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.